

N=122

2023

Mainguy M, Le Page E, Michel L, **Leray E**. Pregnancy-related healthcare utilization among women with multiple sclerosis. *Front Neurol*. 2023 Feb 16;14:1129117. doi: 10.3389/fneur.2023.1129117.

Lebrun-Fréney C, Okuda DT, Siva A, Landes-Chateau C, Azevedo CJ, Mondot L, Carra-Dallière C, Zephir H, Louapre C, Durand-Dubief F, Le Page E, Bensa C, Ruet A, Ciron J, Laplaud DA, Casez O, Mathey G, de Seze J, Zeydan B, Makhani N, Tutuncu M, Levraut M, Cohen M, Thouvenot E, Pelletier D, Kantarci OH; RISC, SFSEP and **OFSEP** investigators. The radiologically isolated syndrome: revised diagnostic criteria. *Brain*. 2023 Mar 2:awad073. doi: 10.1093/brain/awad073.

2022

Sabathé C, Casey R, Vukusic S, **Leray E**, Mathey G, De Sèze J, Ciron J, Wiertlewski S, Ruet A, Pelletier J, Zéphir H, Michel L, Lebrun-Frenay C, Moisset X, Thouvenot E, Camdessanché JP, Bakchine S, Stankoff B, Al Khedr A, Cabre P, Maillart E, Berger E, Heinzlef O, Hankiewicz K, Moreau T, Gout O, Bourre B, Wahab A, Labauge P, Montcuquet A, Defer G, Maurousset A, Maubeuge N, Dimitri Boulous D, Ben Nasr H, Nifle C, Casez O, Laplaud DA, Foucher Y. Improving the decision to switch from first to second-line therapy in Multiple Sclerosis: a dynamic scoring system. *Mult Scler*. 2022 Dec 14:13524585221139156. doi: 10.1177/13524585221139156.

Wilson S, Calocer F, Rollot F, Fauvernier M, Remontet L, Tron L, Vukusic S, Le Page E, Debouverie M, Ciron J, Ruet A, De Sèze J, Zephir H, Moreau T, Lebrun-Fréney C, Laplaud DA, Clavelou P, Labauge P, Berger E, Pelletier J, Heinzlef O, Thouvenot E, Camdessanché JP, **Leray E**, Dejardin O, Defer G. Effects of socioeconomic status on excess mortality in patients with multiple sclerosis in France: A retrospective observational cohort study. *Lancet Reg Health Eur*. 2022 Nov 17;24:100542. doi: 10.1016/j.lanep.2022.100542.

Medioni J, Scimeca D, Marquez YL, **Leray E**, Dalichampt M, Hoertel N, Bennani M, Trempat P, Boujedaini N. Benefits of Homeopathic Complementary Treatment in Patients With Breast Cancer: A Retrospective Cohort Study Based on the French Nationwide Healthcare Database. *Clin Breast Cancer*. 2022 Oct 8:S1526-8209(22)00224-5. doi: 10.1016/j.clbc.2022.10.001.

Vukusic S, Marignier R, Ciron J, Bourre B, Cohen M, Deschamps R, Guillaume M, Kremer L, Pique J, Carra-Dalliere C, Michel L, **Leray E**, Guennoc AM, Laplaud D, Androdias G, Bensa C, Bigaut K, Biotti D, Branger P, Casez O, Daval E, Donze C, Dubessy AL, Dulau C, Durand-Dubief F, Hebant B, Kwiatkowski A, Lannoy J, Maarouf A, Manchon E, Mathey G, Moisset X, Montcuquet A, Roux T, Maillart E, Lebrun-Frenay C. Pregnancy and neuromyelitis optica spectrum disorders: 2022 recommendations from the French Multiple Sclerosis Society. *Mult Scler*. 2022 Nov 8:13524585221130934. doi: 10.1177/13524585221130934.

Vukusic S, Carra-Dalliere C, Ciron J, Maillart E, Michel L, **Leray E**, Guennoc AM, Bourre B, Laplaud D, Androdias G, Bensa C, Bigaut K, Biotti D, Branger P, Casez O, Cohen M, Daval E, Deschamps R, Donze C, Dubessy AL, Dulau C, Durand-Dubief F, Guillaume M, Hebant B, Kremer L, Kwiatkowski A, Lannoy J, Maarouf A, Manchon E, Mathey G, Moisset X, Montcuquet A, Pique J, Roux T, Marignier R, Lebrun-Frenay C. Pregnancy and multiple sclerosis: 2022 recommendations from the French multiple sclerosis society. *Mult Scler*. 2022 Nov 1:13524585221129472. doi: 10.1177/13524585221129472.

Calocer F, Ng HS, Zhu F, Zhao Y, Dejardin O, **Leray E**, Defer G, Evans C, Fisk JD, Marrie RA, Tremlett H. Low socioeconomic status was associated with a higher mortality risk in multiple sclerosis. *Mult Scler*. 2022 Oct 25;13524585221129963. doi: 10.1177/13524585221129963.

Lescot L, Lefort M, Leguy S, Le Page E, Vukusic S, Edan G, Kerbrat A, Lebrun-Frenay C, De Sèze J, Laplaud DA, Wiertlewski S, **Leray E***, Michel L*. Disease modifying therapies and disease activity during pregnancy and postpartum in a contemporary cohort of relapsing Multiple Sclerosis patients. *Mult Scler Relat Disord*. 2022 Aug 15;68:104122. doi: 10.1016/j.msard.2022.104122.

Mainguy M, Tillaut H, Degremont A, Le Page E, Mainguy C, Duros S, Polard E, **Leray E**. Assessing the Risk of Relapse Requiring Corticosteroids After In Vitro Fertilization in Women With Multiple Sclerosis. *Neurology*. 2022 Aug 11;10.1212/WNL.000000000201027.

Roos I, Malpas C, **Leray E**, Casey R, Horakova D, Havrdova EK, Debouverie M, Patti F, De Seze J, Izquierdo G, Eichau S, Edan G, Prat A, Girard M, Ozakbas S, Grammond P, Zephir H, Ciron J, Maillart E, Moreau T, Amato MP, Labauge P, Alroughani R, Buzzard K, Skibina O, Terzi M, Laplaud DA, Berger E, Grand'Maison F, Lebrun-Frenay C, Cartechini E, Boz C, Lechner-Scott J, Clavelou P, Stankoff B, Prevost J, Kappos L, Pelletier J, Shaygannejad V, Yamout BI, Khoury SJ, Gerlach O, Spitaleri DLA, Van Pesch V, Gout O, Turkoglu R, Heinzlef O, Thouvenot E, McCombe PA, Soysal A, Bourre B, Slee M, Castillo-Trivino T, Bakchine S, Ampapa R, Butler EG, Wahab A, Macdonell RA, Aguera-Morales E, Cabre P, Ben NH, Van der Walt A, Laureys G, Van Hijfte L, Ramo-Tello CM, Maubeuge N, Hodgkinson S, Sánchez-Menoyo JL, Barnett MH, Labeyrie C, Vucic S, Sidhom Y, Gouider R, Csepany T, Sotoca J, de Gans K, Al-Asmi A, Fragoso YD, Vukusic S, Butzkueven H, Kalincik T; MSBase; OFSEP. Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis. *Neurology*. 2022 Aug 17;10.1212/WNL.000000000201029.

Callens A, Leblanc S, Le Page E, Edan G, Jourdain A, Coustans M, Wiertlewski S, Laplaud D, Videt D, Lallement F, **Leray E***, Michel L*. Disease reactivation after fingolimod cessation in Multiple Sclerosis patients with pregnancy desire: A retrospective study. *Mult Scler Relat Disord*. 2022 Jul 22;66:104066. doi: 10.1016/j.msard.2022.104066.

Leguy S, Lefort M, Lescot L, Michaud A, Vukusic S, Le Page E, Edan G, Kerbrat A, Lebrun-Frenay C, De Sèze J, Laplaud DA, Wiertlewski S, **Leray E**, Michel L. COPP-MS: COrticosteroids during the Post-Partum in relapsing Multiple Sclerosis patients. *J Neurol*. 2022 Jun 23. doi: 10.1007/s00415-022-11215-7.

Lefort M, Vukusic S, Casey R, Edan G, **Leray E**; OFSEP investigators. Disability Progression in Multiple Sclerosis Patients using Early First-line Treatments. *Eur J Neurol*. 2022 May 26. doi: 10.1111/ene.15422.

Lefort M, Sharmin S, Andersen JB, Vukusic S, Casey R, Debouverie M, Edan G, Ciron J, Ruet A, De Sèze J, Maillart E, Zephir H, Labauge P, Defer G, Lebrun-Frenay C, Moreau T, Berger E, Clavelou P, Pelletier J, Stankoff B, Gout O, Thouvenot E, Heinzlef O, Al-Khedr A, Bourre B, Casez O, Cabre P, Montcuquet A, Wahab A, Camdessanché JP, Maurousset A, Ben Nasr H, Hankiewicz K, Pottier C, Maubeuge N, Dimitri-Boulos D, Nifle C, Laplaud DA, Horakova D, Havrdova EK, Alroughani R, Izquierdo G, Eichau S, Ozakbas S, Patti F, Onofrij M, Lugaresi A, Terzi M, Grammond P, Grand'Maison F, Yamout B, Prat A, Girard M, Duquette P, Boz C, Trojano M, McCombe P, Slee M, Lechner-Scott J, Turkoglu R, Sola P, Ferraro D, Granella F, Shaygannejad V, Prevost J, Maimone D, Skibina O, Buzzard K, Van der Walt A, Karabudak R, Van Wijmeersch B, Csepany T, Spitaleri D, Vucic S, Koch-Henriksen N, Sellebjerg F, Soerensen PS, Hilt Christensen CC, Rasmussen PV, Jensen MB, Frederiksen JL, Bramow S, Mathiesen HK, Schreiber KI, Butzkueven H, Magyari M, Kalincik T, **Leray E**. Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis. *BMC Med Res Methodol*. 2022 May 30;22(1):155. doi: 10.1186/s12874-022-01623-8.

Leblanc S, Lefort M, Le Page E, Michel L, **Leray E**. Trends in disease-modifying therapy use in patients with multiple sclerosis using a 10-year population-based cohort study in France. *Expert Rev Neurother*. 2022 Apr 5:1-8. doi: 10.1080/14737175.2022.2061950.

Degremont A, Kerbrat S, Balusson F, Jonville-Bera AP, Ringa V, Travers D, Tillaut H, **Leray E**, Oger E, Birben A, Polard E. Prescribing Trends for Valproate Among Pregnant Women: A Cross-sectional Study in 2013 and 2016 Using the French Health Insurance Database. *Neurology*. 2022 Apr 4;10.1212/WNL.0000000000200260. doi: 10.1212/WNL.0000000000200260.

Rollot F, Couturier J, Casey R, Wiertlewski S, Debouverie M, Pelletier J, De Sèze J, Labauge P, Ruet A, Thouvenot E, Ciron J, Berger E, Gout O, Clavelou P, Stankoff B, Casez O, Bourre B, Zephir H, Moreau T, Lebrun-Frenay C, Maillart E, Edan G, Neau JP, Montcuquet A, Cabre P, Camdessanché JP, Defer G, Nasr HB, Maurousset A, Hankiewicz K, Pottier C, **Leray E**, Vukusic S, Laplaud DA. Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing-Remitting Multiple Sclerosis After Fingolimod Withdrawal. *Neurotherapeutics*. 2022 Feb 25. doi: 10.1007/s13311-022-01202-1.

Papeix C, Castelnovo G, **Leray E**, Coustans M, Levy P, Visy JM, Kobelt G, Lamy F, Allaf B, Heintzmann F, Chouette I, Raponi E, Durand B, Grevat E, Kamar D, Debouverie M, Lebrun-Frenay C; Virgile Study Group. Long-Term Effectiveness, Safety and Tolerability of Fingolimod in Patients with Multiple Sclerosis in Real-World Treatment Settings in France: The VIRGILE Study. *Neurol Ther*. 2022 Feb 11. doi: 10.1007/s40120-022-00334-y.

Lefort M, Le Corre G, Le Page E, Rizzato C, Le Port D, Michel L, Kerbrat A, **Leray E**, Edan G. Ten-year follow-up after mitoxantrone induction for early highly active relapsing-remitting multiple sclerosis: An observational study of 100 consecutive patients. *Rev Neurol (Paris)*. 2022 Feb 15:S0035-3787(22)00043-1. doi: 10.1016/j.neurol.2021.11.014.

2021

Grimaud O, Bayat S, Renault A, Maury E, Pottecher J, Dolz M, Braun F, Fermanian C, Ricard-Hibon A, Prieto N, Philippe JM, **Leray E**. TRANSCOV cohort protocol: an epidemiological study assessing the impact of critically ill COVID-19 patients long distance transfers between intensive care units. *BMJ Open*. 2021 Oct 21;11(10):e054774. doi: 10.1136/bmjopen-2021-054774.

Sanchez MA, Vuagnat A, Grimaud O, **Leray E**, Philippe JM, Lescure FX, Boutonnet M, Coignard H, Hibon AR, Sanchez S, Pottecher J. Impact of ICU transfers on the mortality rate of patients with COVID-19: insights from comprehensive national database in France. *Ann Intensive Care*. 2021 Oct 26;11(1):151. doi: 10.1186/s13613-021-00933-2.

Lebrun-Frény C, Rollot F, Mondot L, Zephir H, Louapre C, Le Page E, Durand-Dubief F, Labauge P, Bensa C, Thouvenot E, Laplaud D, de Seze J, Ciron J, Bourre B, Cabre P, Casez O, Ruet A, Mathey G, Berger E, Moreau T, Al Khedr A, Derache N, Clavelou P, Guennoc AM, Créange A, Neau JP, Tourbah A, Camdessanché JP, Maarouf A, Callier C, Vermersch P, Kantarci O, Siva A, Azevedo C, Makhani N, Cohen M, Pelletier D, Okuda D, Vukusic S; RISC, SFSEP, and **OFSEP Investigators**. Risk Factors and Time to Clinical Symptoms of Multiple Sclerosis Among Patients With Radiologically Isolated Syndrome. *JAMA Netw Open*. 2021 Oct 1;4(10):e2128271. doi: 10.1001/jamanetworkopen.2021.28271.

Sharmin S, Lefort M, Andersen JB, **Leray E**, Horakova D, Havrdova EK, Alroughani R, Izquierdo G, Ozakbas S, Patti F, Onofrij M, Lugaresi A, Terzi M, Grammond P, Grand'Maison F, Yamout B, Prat A, Girard M, Duquette P, Boz C, Trojano M, McCombe P, Slee M, Lechner-Scott J, Turkoglu R, Sola P, Ferraro D, Granella F, Prevost J, Maimone D, Skibina O, Buzzard K, Van der Walt A, Van Wijmeersch B, Csepány T, Spitaleri D, Vucic S, Casey R, Debouverie M, Edan G, Ciron J, Ruet A, De Sèze J, Maillart E, Zephir H, Labauge P, Defer G, Lebrun-Frény C, Moreau T, Berger E, Clavelou P, Pelletier J, Stankoff B, Gout O, Thouvenot E, Heinzlef O, Al-Khedr A, Bourre B, Casez O, Cabre P, Montcuquet A, Wahab A, Camdessanché JP, Maurousset A, Patry I, Hankiewicz K, Pottier C, Maubeuge N, Labeyrie C, Nifle C, Laplaud D, Koch-Henriksen N, Sellebjerg FT, Soerensen PS, Pflieger CC, Rasmussen PV, Jensen MB, Frederiksen JL, Bramow S, Mathiesen HK, Schreiber KI, Magyari M, Vukusic S, Butzkueven H, Kalincik T; Danish Multiple Sclerosis Registry, OFSEP and the MSBase investigators. Natalizumab

Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts. *CNS Drugs*. 2021 Sep 18. doi: 10.1007/s40263-021-00860-7.

Tillaut H, Degrémont A, Kerbrat S, Roux J, Le Page E, Mainguy C, Duros S, Polard E, **Leray E**. Pregnancy in women with multiple sclerosis in France from 2010 to 2015: Incidence, outcomes, and exposure to disease-modifying therapies. *Mult Scler*. 2021 Aug 19:13524585211035376. doi: 10.1177/13524585211035376.

Andersen JB, Sharmin S, Lefort M, Koch-Henriksen N, Sellebjerg F, Sørensen PS, Hilt Christensen CC, Rasmussen PV, Jensen MB, Frederiksen JL, Bramow S, Mathiesen HK, Schreiber KI, Horakova D, Havrdova EK, Alroughani R, Izquierdo G, Eichau S, Ozakbas S, Patti F, Onofrij M, Lugaresi A, Terzi M, Grammond P, Grand Maison F, Yamout B, Prat A, Girard M, Duquette P, Boz C, Trojano M, McCombe P, Slee M, Lechner-Scott J, Turkoglu R, Sola P, Ferraro D, Granella F, Shaygannejad V, Prevost J, Skibina O, Solaro C, Karabudak R, Wijmeersch BV, Csepány T, Spitaleri D, Vucic S, Casey R, Debouverie M, Edan G, Ciron J, Ruet A, Sèze JD, Maillart E, Zephir H, Labauge P, Defer G, Lebrun C, Moreau T, Berger E, Clavelou P, Pelletier J, Stankoff B, Gout O, Thouvenot E, Heinzlief O, Al-Khedr A, Bourre B, Casez O, Cabre P, Montcuquet A, Wahab A, Camdessanché JP, Marousset A, Patry I, Hankiewicz K, Pottier C, Maubeuge N, Labeyrie C, Nifle C, **Leray E**, Laplaud DA, Butzkueven H, Kalincik T, Vukusic S, Magyari M. The effectiveness of natalizumab vs fingolimod-A comparison of international registry studies. *Mult Scler Relat Disord*. 2021 May 8;53:103012. doi: 10.1016/j.msard.2021.103012.

S. Leblanc, J. Roux, H. Tillaut, E. Le Page, **E. Leray**. Disease-modifying therapy usage in patients with multiple sclerosis: a 6-year population-based study. *Rev Neurol (Paris)*. 2021 Jul 9:S0035-3787(21)00587-7. doi: 10.1016/j.neurol.2021.04.006.

Roos I, **Leray E**, Casey R, Horakova D, Havrdova E, Izquierdo G, Madueño S, Patti F, Edan G, Debouverie M, Pelletier J, Ozakbas S, Amato MP, Clavelou P, Grammond P, Boz C, Buzzard K, Skibina O, Ciron J, Gerlach O, Grand'Maison F, Lechner-Scott J, Malpas C, Butzkueven H, Vukusic S, Kalincik T, on behalf of the MSBase and OFSEP study groups. Effects of high and low efficacy therapy in secondary progressive multiple sclerosis. *Neurology*. 2021 Aug 31;97(9):e869-e880. doi: 10.1212/WNL.0000000000012354.

J. Roux, E. Kingwell, F. Zhu, H. Tremlett, **E. Leray**, and the BeAMS Study group. Care consumption of people with multiple sclerosis in British Columbia, Canada: a multichannel sequence analysis in a population-based setting. *Mult Scler*. 2021 May 28:13524585211016726. doi: 10.1177/13524585211016726.

F. Rollot, M. Fauvernier, Z. Uhry, S. Vukusic, N. Bossard, L. Remontet, **E. Leray** on behalf of the OFSEP investigators. Effects of age and disease duration on excess mortality in patients with multiple sclerosis from a French nationwide cohort. *Neurology*. 2021 Jul 27;97(4):e403-e413. doi: 10.1212/WNL.0000000000012224.

Roos I, **Leray E**, Frascoli F, Casey R, Brown JW, Horakova D, Havrdova EK, Trojano M, Patti F, Izquierdo G, Eichau S, Onofrij M, Lugaresi A, Prat A, Girard M, Grammond P, Sola P, Ferraro D, Ozakbas S, Bergamaschi R, Sá MJ, Cartechini E, Boz C, Granella F, Hupperts R, Terzi M, Lechner-Scott J, Spitaleri D, Van Pesch V, Soysal A, Olascoaga J, Prevost J, Aguera-Morales E, Slee M, Csepány T, Turkoglu R, Sidhom Y, Gouider R, Van Wijmeersch B, McCombe P, Macdonell R, Coles A, Malpas CB, Butzkueven H, Vukusic S, Kalincik T; MSBase; OFSEP investigators. Determinants of therapeutic lag in multiple sclerosis. *Mult Scler*. 2021 Jan 11:1352458520981300. doi: 10.1177/1352458520981300.

F. Rollot, R. Casey, **E. Leray**, M. Debouverie, G. Edan, S. Wiertlewski, S. Vukusic, D.A. Laplaud. Cumulative effects of therapies on disability in relapsing multiple sclerosis. *Mult Scler*. 2021 Jan 6:1352458520980366. doi: 10.1177/1352458520980366.

2020

Sommer AJ, **Leray E**, Lee Y, Bind MC. Assessing environmental epidemiology questions in practice with a causal inference pipeline: An investigation of the air pollution-multiple sclerosis relapses relationship. *Stat Med*. 2020 Dec 16. doi: 10.1002/sim.8843.

Walton C, King R, Rechtman L, Kaye W, **Leray E**, Marrie RA, Robertson N, La Rocca N, Uitdehaag B, van der Mei I, Wallin M, Helme A, Angood Napier C, Rijke N, Baneke P. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. *Mult Scler*. 2020 Nov 11:1352458520970841. doi: 10.1177/1352458520970841.

Lefort M, Foucher Y, Lenain R, Vukusic S, Edan G, **Leray E**. Long-term effect of first-line injectable multiple sclerosis treatments: Input of a time-dependent propensity score. *Pharmacoepidemiol Drug Saf*. 2020 Oct 19. doi: 10.1002/pds.5154.

Barataud-Reilhac A, Kerbrat S, Roux J, Guilleux A, Polard E, **Leray E**. Teriflunomide-exposed pregnancies in a French cohort of patients with multiple sclerosis. *Neurol Clin Pract*. 2020 Aug;10(4):287-297. doi: 10.1212/CPJ.0000000000000717.

Donzé C, Papeix C, Lebrun-Frenay C; **French Group for Recommendations in Multiple Sclerosis (France4MS)**; Société francophone de la sclérose en plaques (SFSEP); SPILF. Urinary tract infections and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society. *Rev Neurol (Paris)*. 2020 Aug 28:S0035-3787(20)30617-2. doi: 10.1016/j.neurol.2020.02.011.

Guilleux A, Roux J, Travers D, **Leray E**. Prevalence of mental disorders is higher in patients with multiple sclerosis than in the general population or in patients with rheumatoid arthritis in France. *Mult Scler J Exp Transl Clin*. 2020;6(3):2055217320941540. doi: 10.1177/2055217320941540. eCollection 2020 Jul-Sep.

Roos I, **Leray E**, Frascoli F, Casey R, Brown JWL, Horakova D, Havrdova EK, Trojano M, Patti F, Izquierdo G, Eichau S, Onofrij M, Lugaresi A, Prat A, Girard M, Grammond P, Sola P, Ferraro D, Ozakbas S, Bergamaschi R, Sá MJ, Cartechini E, Boz C, Granella F, Hupperts R, Terzi M, Lechner-Scott J, Spitaleri D, Van Pesch V, Soysal A, Olascoaga J, Prevost J, Aguera-Morales E, Slee M, Csepany T, Turkoglu R, Sidhom Y, Gouider R, Van Wijmeersch B, McCombe P, Macdonell R, Coles A, Malpas CB, Butzkueven H, Vukusic S, Kalincik T; MSBase; OFSEP investigators. [Delay from treatment start to full effect of immunotherapies for multiple sclerosis](#). *Brain*. 2020 Sep 1;143(9):2742-2756. doi: 10.1093/brain/awaa231.

Kovess-Masfety V, Balusson F, **Leray E**, Husky M, Scailteux LM. Prescription patterns of first- and second-generation antipsychotic drugs in the French population. *Fundam Clin Pharmacol*. 2020 Oct;34(5):603-611. doi: 10.1111/fcp.12553.

Havas J, **Leray E**, Rollot F, Casey R, Michel L, Lejeune F, Wiertlewski S, Laplaud D, Foucher Y. Predictive medicine in multiple sclerosis: A systematic review. *Mult Scler Relat Disord*. 2020 Jan 2;40:101928. doi: 10.1016/j.msard.2020.101928.

2019

Roux J, Guilleux A, Lefort M, **Leray E**. Use of health care services from patients with multiple sclerosis in France over 2010-2015: a nationwide population-based study using health administrative data. *Mult Scler J Exp Transl Clin*. 2019 Dec 18;5(4):2055217319896090. doi: 10.1177/2055217319896090.

Couloume L, Barbin L, **Leray E**, Wiertlewski S, Le Page E, Kerbrat A, Ory S, Le Port D, Edan G, Laplaud DA, Michel L. High-dose biotin in progressive multiple sclerosis: A prospective study of 178 patients in routine clinical practice. *Mult Scler*. 2019 Dec 17:1352458519894713. doi: 10.1177/1352458519894713.

Vukusic S, Rollot F, Casey R, Pique J, Marignier R, Mathey G, Edan G, Brassat D, Ruet A, De Sèze J, Maillart E, Zéphir H, Labauge P, Derache N, Lebrun-Frenay C, Moreau T, Wiertlewski S, Berger E, Moisset X, Rico-Lamy A, Stankoff B, Bensa C, Thouvenot E, Heinzlef O, Al-Khedr A, Bourre B, Vaillant M, Cabre P, Montcuquet A, Wahab A, Camdessanché JP, Tourbah A, Guennoc AM, Hankiewicz K, Patry I, Nifle C, Maubeuge N, Labeyrie C, Vermersch P, Laplaud DA; **OFSEP Investigators**. Progressive Multifocal Leukoencephalopathy Incidence and

Risk Stratification Among Natalizumab Users in France. *JAMA Neurol.* 2019 Sep 3. doi: 10.1001/jamaneurol.2019.2670. [Epub ahead of print]

Laplaud DA, Casey R, Barbin L, Debouverie M, De Sèze J, Brassat D, Wiertlewski S, Brochet B, Pelletier J, Vermersch P, Edan G, Lebrun-Frenay C, Clavelou P, Thouvenot E, Camdessanché JP, Tourbah A, Stankoff B, Al Khedr A, Cabre P, Lubetzki C, Papeix C, Berger E, Heinzlef O, Debroucker T, Moreau T, Gout O, Bourre B, Wahab A, Labauge P, Magy L, Defer G, Guennoc AM, Maubeuge N, Labeyrie C, Patry I, Nifle C, Casez O, Michel L, Rollot F, **Leray E**, Vukusic S, Foucher Y; SFSEP and OFSEP groups. Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis. *Neurology.* 2019 Aug 13;93(7):e635-e646. doi: 10.1212/WNL.0000000000007938. Epub 2019 Jul 12.

Ahrweiller K, Rousseau C, Le Page E, Bajoux E, **Leray E**, Michel L, Edan G, Kerbrat A. Decreasing impact of late relapses on disability worsening in secondary progressive multiple sclerosis. *Mult Scler.* 2019 May 16:1352458519848090. doi: 10.1177/1352458519848090.

Kingwell E, **Leray E**, Zhu F, Petkau J, Edan G, Oger J, Tremlett H. Multiple sclerosis: effect of beta interferon treatment on survival. *Brain.* 2019 May 1;142(5):1324-1333. doi: 10.1093/brain/awz055.

Lebrun C, Vukusic S; **French Group for Recommendations in Multiple Sclerosis (France4MS)** and the Société Francophone de la Sclérose En Plaques (SFSEP). Immunization and multiple sclerosis: Recommendations from the French multiple sclerosis society. *Mult Scler Relat Disord.* 2019 Jun;31:173-188. doi: 10.1016/j.msard.2019.04.004. Epub 2019 Apr 10. Review.

Lebrun C, Vukusic S; **French Group for Recommendations in Multiple Sclerosis (France4MS)**, the Société francophone de la sclérose en plaques (SFSEP). Immunization and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society. *Rev Neurol (Paris).* 2019 Jun;175(6):341-357. doi: 10.1016/j.neurol.2019.04.001. Epub 2019 Apr 27.

2018

Schlegel V, **Leray E**. From Medical Prescription To Multiple Sclerosis Patients' Compliance: A Qualitative Insight Into The Neurologist-Patient Relationship. *Int J MS Care.* 2018 Nov-Dec;20(6):279-286. doi: 10.7224/1537-2073.2017-043.

Bajoux E, Klemanski DH, Husky M, **Leray E**, Chan Chee C, Shojaei T, Fermanian C, Kovess-Masfety V. Factors Associated with Parent-Child Discrepancies in Reports of Mental Health Disorders in Young Children. *Child Psychiatry Hum Dev.* 2018 Jun 5. doi: 10.1007/s10578-018-0815-7. [Epub ahead of print]

Roux J, Grimaud O, **Leray E**. Use of state sequence analysis for care pathway analysis: The example of multiple sclerosis. *Stat Methods Med Res.* 2019 Jun;28(6):1651-1663. doi: 10.1177/0962280218772068.

Jeanjean M, Bind MA, Roux J, Ongagna JC, de Sèze J, Bard D, **Leray E**. Ozone, NO₂ and PM₁₀ are associated with the occurrence of multiple sclerosis relapses. Evidence from seasonal multi-pollutant analyses. *Environ Res.* 2018 May;163:43-52. doi: 10.1016/j.envres.2018.01.040. Epub 2018 Feb 6.

2017

Roux J, Bard D, Le Pabic E, Segala C, Reis J, Ongagna JC, de Sèze J, **Leray E**. Air pollution by particulate matter PM₁₀ may trigger multiple sclerosis relapses. *Environ Res*. 2017 Jul;156:404-410. doi: 10.1016/j.envres.2017.03.049. Epub 2017 Apr 11.

Gallini A, Moisan F, Maura G, Carcaillon-Bentata L, **Leray E**, Haesebaert J, Bruandet A, Moutengou E, Luciano L, Weill A, Marin B, Gardette V. [Identification of neurodegenerative diseases in administrative databases in France: A systematic review of the literature]. *Rev Epidemiol Sante Publique*. 2017 Oct;65 Suppl 4:S183-S197. doi: 0.1016/j.respe.2017.01.115. Epub 2017 Mar 22. Review. French.

Kalson-Ray S, Edan G, **Leray E**; SURVIMUS Study Group. An excessive risk of suicide may no longer be a reality for multiple sclerosis patients. *Mult Scler*. 2017 May;23(6):864-871. doi: 10.1177/1352458517699873. Epub 2017 Mar 16.

2016

Pivot D, Debouverie M, Grzebyk M, Brassat D, Clanet M, Clavelou P, Confavreux C, Edan G, **Leray E**, Moreau T, Vukusic S, Hédelin G, Guillemin F. Geographical Heterogeneity of Multiple Sclerosis Prevalence in France. *PLoS One*. 2016 Dec 9;11(12):e0167556. doi: 10.1371/journal.pone.0167556.

Kovess-Masfety V, **Leray E**, Denis L, Husky M, Pitrou I, Bodeau-Livinec F. Mental health of college students and their non-college-attending peers: results from a large French cross-sectional survey. *BMC Psychol*. 2016 Apr 21;4:20. doi: 10.1186/s40359-016-0124-5.

Barbin L, Rousseau C, Jousset N, Casey R, Debouverie M, Vukusic S, De Sèze J, Brassat D, Wiertlewski S, Brochet B, Pelletier J, Vermersch P, Edan G, Lebrun-Frenay C, Clavelou P, Thouvenot E, Camdessanché JP, Tourbah A, Stankoff B, Al Khedr A, Cabre P, Papeix C, Berger E, Heinzlief O, Debroucker T, Moreau T, Gout O, Bourre B, Créange A, Labauge P, Magy L, Defer G, Foucher Y, Laplaud DA; CFSEP and **OFSEP groups**. Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study. *Neurology*. 2016 Feb 23;86(8):771-8. doi: 10.1212/WNL.0000000000002395. Epub 2016 Jan 29.

Leray E, Moreau T, Fromont A, Edan G. Epidemiology of multiple sclerosis. *Rev Neurol (Paris)*. 2016 Jan;172(1):3-13. doi: 10.1016/j.neurol.2015.10.006. Epub 2015 Dec 21.

Calderón-Garcidueñas L, **Leray E**, Heydarpour P, Torres-Jardón R, Reis J. Air pollution, a rising environmental risk factor for cognition, neuroinflammation and neurodegeneration: The clinical impact on children and beyond. *Rev Neurol (Paris)*. 2016 Jan;172(1):69-80. doi: 10.1016/j.neurol.2015.10.008. Epub 2015 Dec 21.

2015

Péron JA, Piolino P, Moal-Boursiquot SL, Biseul I, **Leray E**, Bon L, Desgranges B, Eustache F, Belliard S. Preservation of Person-Specific Semantic Knowledge in Semantic Dementia: Does Direct Personal Experience Have a Specific Role? *Front Hum Neurosci*. 2015 Nov 19;9:625. doi: 10.3389/fnhum.2015.00625. eCollection 2015.

Clesse F, **Leray E**, Bodeau-Livinec F, Husky M, Kovess-Masfety V. Bereavement-related depression: did the changes induced by DSM-V make a difference? Results from a large population-based survey of French residents. *J Affect Disorders* 2015 Aug 15;182:82-90. doi: 10.1016/j.jad.2015.04.039. Epub 2015 Apr 30.

Leray E, Vukusic S, Debouverie M, Clanet M, Brochet B, Sèze Jd, et al. (2015) Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study. *PLoS ONE* 10(7): e0132033.doi:10.1371/journal.pone.0132033

Le Page E, Deburghgraeve V, Lester MA, Cardiet I, **Leray E**, Edan G. Alemtuzumab as rescue therapy in a cohort of 16 aggressive multiple sclerosis patients previously treated by Mitoxantrone: an observational study. *J Neurol*. 2015 Feb 21. [Epub ahead of print]

Caucheteux N, Maarouf A, Genevray M, **Leray E**, Deschamps R, Chaunu MP, Daelman L, Ferré JC, Gout O, Pelletier J, Pierot L, Edan G, Tourbah A. Criteria improving multiple sclerosis diagnosis at the first MRI. *J Neurol*. 2015 Feb 17. [Epub ahead of print]

duRivage N, Keyes K, **Leray E**, Pez O, Bitfoi A, Koç C, Goelitz D, Kuijpers R, Lesinskiene S, Mihova Z, Otten R, Fermanian C, Kovess-Masfety V. Parental Use of Corporal Punishment in Europe: Intersection between Public Health and Policy. *PLoS One*. 2015 Feb 12;10(2):e0118059. doi: 10.1371/journal.pone.0118059. eCollection 2015.

Kovess V, Choppin S, Gao F, Pivette M, Husky M, **Leray E**. Psychotropic medication use in French children and adolescents. *J Child Adolesc Psychopharmacol*. 2015 Mar;25(2):168-75. doi: 10.1089/cap.2014.0058. Epub 2015 Jan 13.

Kerbrat A, Hamonic S, **Leray E**, Tron I, Edan G, Yaouanq J; West Neuroscience Network of Excellence (WENNE). Ten-year prognosis in multiple sclerosis: a better outcome in relapsing-remitting patients but not in primary progressive patients. *Eur J Neurol*. 2015 Mar;22(3):507-e35. doi: 10.1111/ene.12600. Epub 2014 Dec 16.

2014 et avant

Yaouanq J, Tron I, Kerbrat A, **Leray E**, Hamonic S, Merienne M, Hinault P, Edan G. Register-based incidence of multiple sclerosis in Brittany (north-western France), 2000-2001. *Acta Neurol Scand*. 2014 Oct 14. doi: 10.1111/ane.12332. [Epub ahead of print]

Grimaud O, **Leray E**, Lalloué B, Aghzaf R, Durier J, Giroud M, Béjot Y. Mortality following stroke during and after acute care according to neighbourhood deprivation: a disease registry study. *J Neurol Neurosurg Psychiatry*. 2014 Dec;85(12):1313-8. doi: 10.1136/jnnp-2013-307283. Epub 2014 Mar 19.

Ract I, Ferré JC, Ronzière T, **Leray E**, Carsin-Nicol B, Gauvrit JY. Improving detection of ischemic lesions at 3Tesla with optimized diffusion-weighted magnetic resonance imaging. *J Neuroradiol*. 2013 Jun 10. doi:p11:S0150-9861(13)00049-7. 10.1016/j.neurad.2013.04.003.

Barbier O, Galaud B, Descamps S, Boisrenoult P, **Leray E**, Lustig S, Bonneville P, Laffargue P, Paillot JL, Rosset P, Neyret P, Saragaglia D, Lapra C; French Society of Orthopaedic Surgery and Traumatology (SoFCOT). Relevancy and reproducibility of magnetic resonance imaging (MRI) interpretation in multiple-ligament injuries and dislocations of the knee. *Orthop Traumatol Surg Res*. 2013;99(3):305-11.

Massengo SA, Cisse M, Guiziou C, **Leray E**, Rajabally YA, Edan G. Knowledge of TIA among general practitioners and emergency department physicians. A questionnaire survey in a French semi-rural area. *Clin Neurol Neurosurg*. 2013 Feb 27. doi:p11:S0303-8467(13)00053-X. 10.1016/j.clineuro.2013.01.026.

Leray E, Coustans M, Le Page E, Yaouanq J, Oger J, Edan G. "Clinically definite benign multiple sclerosis", an unwarranted conceptual hodgepodge: evidence from a 30-year observational study. *Mult Scler*. 2013;19(4):458-65.

Drapier S, Gillioz AS, **Leray E**, Péron J, Rouaud T, Marchand A, Vérin M. Apomorphine infusion in advanced Parkinson's patients with subthalamic stimulation contraindications. *Parkinsonism Relat Disord*. 2012;18(1):40-4.

Kerbrat A, Le Page E, **Leray E**, Anani T, Coustans M, Desormeaux C, Guiziou C, Kassiotis P, Lallement F, Laplaud D, Diraison P, Rouhart P, Sartori E, Wardi R, Wiertelwski S, Edan G. Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing remitting multiple sclerosis patients. *J Neurol Sci* 2011; 308(1-2): 98-102.

Edan G, Comi G, Le Page E, **Leray E**, Rocca MA, Filippi M, for the French-Italian Mitoxantrone Interferon beta 1b Trial group. Mitoxantrone prior to interferon-beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial. *J Neurol Neurosurg Psychiatry* 2011;82(12):1344-50.

Le Page E, **Leray E**, Edan G, for the French Mitoxantrone Safety group. Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study. *Mult Scler* 2011;17(7):867-75.

Peron J, El Tamer S, Grandjean D, **Leray E**, Travers D, Drapier D, Verin M, Millet B. Major depressive disorder skews the recognition of emotional prosody. *Prog neuropsychopharmacol Biol Psychiatry* 2011;35(4):987-96.

Edan G, **Leray E**. A new treatment era in multiple sclerosis: clinical applications of new concepts. *J Neurol Sci* 2011;306(1-2):170-2.

Leray E, Yaouanq J, Le Page E, Coustans M, Laplaud D, Oger J, Edan G. Evidence for a two-stage disability progression in multiple sclerosis. *Brain* 2010; 133: 1900-13.

Leray E, Camara A, Drapier D, Riou F, Bougeant N, Pelissolo A, Lloyd K, Bellamy V, Roelandt JL, Millet B. Prevalence, characteristics and comorbidities of anxiety disorders in France: results from the Mental Health in General Population survey (MHGP). *Eur Psychiatry* 2011;26(6):339-45.

Le Jeune F, Verin M, N'Diaye K, Drapier D, **Leray E**, Tezenas S, Baup N, Pelissolo A, Polosan M, Mallet L, Yelnik J, Devaux B, Fontaine D, Chereau I, Bourguignon A, Peron J, Sauleau P, Raoul S, Garin E, Kreps MO, Jaafari N, Millet B. Decrease of prefrontal metabolism after subthalamic stimulation in obsessive-compulsive disorder: a positron emission tomography study. *Biol Psychiatry* 2010; 68(11): 1016-22.

Buffet-Bataillon S, **Leray E**, Poisson M, Michelet C, Bonnaure-Mallet M, Cormier M. Influence of job seniority, hand hygiene education, and patient-to-nurse ratio on hand disinfection compliance. *J Hosp Infect* 2010 ; 76(1): 32-5.

De Saint-Steban C, **Leray E**, Jouan H, Loget P, Venisse An, Roussey M. Peut-on expliquer la mort inattendue du nourrisson ? Réflexions à partir d'une série de 80 cas autopsiés au CHU de Rennes entre 1994 et 2007. *Arch Pediatr* 2010 ; 17(8): 1231-6.

Heresbach D, **Leray E**, d'Halluin PN, Cholet F, Lapalus MG, Gaudric M, Ben Soussan E, Gaudin JL, Vahedi K, Quentin V, Filoche B, Saurin JC, Chaussade S, Ponchon T. Diagnostic accuracy of esophageal capsule endoscopy versus conventional upper digestive endoscopy for suspected esophageal squamous cell carcinoma. *Endoscopy* 2010; 42(2): 93-7.

Beucher J, **Leray E**, Deneuille E, Roblin M, Pin I, Bremont F, Turck D, Ginies JL, Foucaud P, Rault G, Derell J, David V, Journel H, Marchand S, Veillard D, Roussey M. Psychological effects of false positive results in cystic fibrosis newborn screening: a 2-year follow-up. *J Pediatr* 2010; 156(5): 771-6.

Samson F, **Leray E**, Cagnard B, Guggenbuhl P, Bridoux-Henno L, Dabadie A. Suivi longitudinal de la densité minérale osseuse depuis le diagnostic dans la maladie de Crohn de l'enfant. *Gastroenterol Clin Biol* 2010; 34(10): 554-61.

Flet L, Polard E, Guillard O, **Leray E**, Allain H, Javaudin L, Edan G. 3,4-Diaminopyridine safety in clinical practice: an observational, retrospective cohort study. *J Neurol* 2010; 257(6): 937-46.

Jonin PY, Vichard H, **Leray E**, Sarazin M, Dubois B, Belliard S, for the PréAl Study group. Long-term retention deficit involvement in prodromal Alzheimer's disease. *Behav Neurol* 2010; 23(4): 169-71.

Péron J, Biseul I, **Leray E**, Vicente S, Lejeune F, Drapier S, Drapier D, Sauleau P, Haegelen C, Vérin M. Subthalamic nucleus stimulation affects fear and sadness recognition in Parkinson's disease. *Neuropsychology* 2010; 24(1): 1-8.

Lustig S, Barbier O, Boisgard S, Boisrenoult P, Bonneville P, Descamps S, Dubrana F, Galaud B, Laffargue P, **Leray E**, Lapra C, Paillot JL, Saragaglia D, Trojani C, Versier G, Rosset P, Neyret P. Dislocations of the knee, complex knee ligament injuries what care? *Rev Chir Orthop Traumatol* 2009; 95(6 Suppl): S177-87.

Lustig S, **Leray E**, Boisrenoult P, Trojani C, Laffargue P, Saragaglia D, Rosset P, Neyret P, for the French Society of Orthopedic Surgery and Traumatology. Dislocation and bicruciate lesions of the knee: epidemiology and acute stage assessment in a prospective series. *Rev Chir Orthop Traumatol*. 2009; 95(8): 614-20.

Boisrenoult P, Lustig S, Bonneville P, **Leray E**, Versier G, Neyret P, Rosset P, Saragaglia D, for the French Society of Orthopedic Surgery and Traumatology (SOFOT). Vascular lesions associated with bicruciate and knee dislocation ligamentous injury. *Rev Chir Orthop Traumatol*. 2009; 95(8): 621-6.

Bretagne JF, Hamonic S, Piette C, Manfredi S, **Leray E**, Durand G, Riou F. Variations between endoscopists in rates of detection of colorectal neoplasia and their impact on a regional screening program based on colonoscopy after fecal occult blood testing. *Gastrointest Endosc*. 2010;71(2):335-41.

Sauleau P, **Leray E**, Rouaud T, Drapier S, Drapier D, Blanchard S, Drillet G, Péron J, Vérin M. Comparison of weight gain and energy intake after subthalamic versus pallidal stimulation in Parkinson's disease. *Mov Disord* 2009; 24(14): 2149-55.

Riffaud L, Saikali S, **Leray E**, Hamlat A, Haegelen C, Vauléon E, Lesimple T. Survival and prognostic factors in a series of adult medulloblastomas. *J Neurosurg* 2009; 111(3):478-87.

Cournu-Rebeix I, Génin E, **Leray E**, Babron MC, Cohen J, Gout C, Alizadeh M, Perdry H, Semana G, Brassat D, Clerget-Darpoux F, Yaouanq J, Edan G, Rosenheim M, Fontaine B. HLA-DRB1(*)15 allele influences the later course of relapsing remitting multiple sclerosis. *Genes Immun*. 2008;9(6):570-4.

Drapier D, Péron J, **Leray E**, Sauleau P, Biseul I, Drapier S, Lejeune F, Travers D, Bourguignon A, Haegelen C, Millet B, Vérin M. Emotion recognition impairment and apathy after subthalamic nucleus stimulation in Parkinson's disease have separate neural substrates. *Neuropsychologia* 2008;46(11):2796-801.

Peron J, Vicente S, **Leray E**, Drapier S, Drapier D, Cohen R, Biseul I, Rouaud T, Lejeune F, Sauleau P, Vérin M. Are dopaminergic pathways involved in theory of mind? A study in Parkinson's disease. *Neuropsychologia* 2009;47(2):406-14.

Le Page E, **Leray E**, Taurin G, Coustans M, Chaperon J, Morrissey SP, Edan G. Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5-year follow-up observational study of 100 consecutive patients. *J Neurol Neurosurg Psychiatry* 2008;79(1):52-6.

Leray E, Morrissey SP, Yaouanq J, Coustans M, Le Page E, Chaperon J, Edan G. Long term survival in patients with multiple sclerosis in West France. *Mult Scler* 2007;13(7):865-74.

Donal E, Vignat N, De Place C, **Leray E**, Crocq C, Mabo P, Daubert JC, Leclercq C. Acute effects of biventricular pacing on right ventricular function assessed by tissue Doppler imaging. *Europace* 2007;9(2):108-12.

Rioux-Leclercq N, Fergelot P, Zerrouki S, **Leray E**, Jouan F, Bellaud P, Epstein J, Patard JJ. Plasma level and tissue expression of vascular endothelial growth factor in renal cell carcinoma: a prospective study of 50 cases. *Hum Pathol*. 2007;38(10):1489-95.

Laplaud DA, Lefrère F, **Leray E**, Barrière P, Wiertlewski S. Le risque de poussée augmente chez les patientes ayant une sclérose en plaques après une stimulation ovarienne. *Gynecol Obstet Fertil*. 2007;35(10):1047-50.

Laplaud DA, **Leray E**, Barrière P, Wiertlewski S, Moreau T. Increase in multiple sclerosis relapse rate following in vitro fertilization. *Neurology* 2006;66(8):1280-1.

Bensalah K, **Leray E**, Fergelot P, Rioux-Leclercq N, Tostain J, Guillé F, Patard JJ. Prognostic value of thrombocytosis in renal cell carcinoma. *J Urol* 2006;175(3):859-63.

Le Page E, **Leray E**, Taurin G, Coustans M, Chaperon J, Edan G. Etude observationnelle de la mitoxantrone dans les formes rémittentes actives de sclérose en plaques : suivi à long terme d'une cohorte de 100 patients consécutifs. *Rev Neurol* 2006;162(2):185-94.

Cornillet A, Camus C, Nimubona S, Gandemer V, Tattevin P, Belleguic C, Chevrier S, Meunier C, Lebert C, Aupée M, Caulet-Maugendre S, Fauchoux M, Lelong B, **Leray E**, Guiguen C, Gangneux JP. Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey. *Clin Infect Dis* 2006;43(5):577-84.

Patard JJ, **Leray E**, Rioux-Leclercq N, Cindolo L, Ficarra V, Zisman A, De La Taille A, Tostain J, Artibani W, Abbou CC, Lobel B, Guillé F, Chopin DK, Mulders PFA, Wood CG, Swanson DA, Figlin RA, Beldegrun AS, Pantuck AJ. The prognostic value of histologic subtypes in Renal Cell Carcinoma (RCC). A multicenter experience in 4063 patients. *J Clin Oncol* 2005;23(12):1763-71.

Rioux-Leclercq N, **Leray E**, Patard JJ, Lobel N, Guillé F, Jouan F, Bellaud P, Epstein J. The utility of Ki-67 expression in the differential diagnosis of prostatic intraepithelial neoplasia and ductal adenocarcinoma. *Hum Pathol* 2005;36(5):531-5.

Lecoq G, Leclercq C, **Leray E**, Crocq C, Alonso C, De Place C, Mabo P, Daubert JC. Clinical and electrocardiographic predictors of a positive response to cardiac resynchronization therapy in advanced heart failure. *Eur Heart J* 2005;26(11):1094-100.

Drapier S, Raoul S, Drapier D, **Leray E**, Lallement F, Rivier I, Sauleau P, Lajat Y, Edan G, Verin M. Only physical aspects of quality of life are significantly improved by bilateral subthalamic stimulation in Parkinson's disease. *J Neurol* 2005;252(5):583-8.

Haegelen C, Morandi X, Riffaud L, Amlashi SFA, **Leray E**, Brassier G. Results for spinal meningioma surgery in patients with severe preoperative neurological deficits. *Eur Spine J* 2005;14(5):440-4.

Guillevin L, Mahr A, Callard P, Godmer P, Pagnoux C, **Leray E**, Cohen P, for the French Vasculitis Study group. Hepatitis B virus-associated polyarteritis nodosa. Clinical characteristics, outcome and impact of treatment in 115 patients. *Medicine (Baltimore)* 2005;84(5):313-22.

Patard JJ, **Leray E**, Cindolo E, Ficarra V, Rodriguez A, De La Taille A, Tostain J, Artibani J, Abbou CC, Guillé F, Chopin D, Lobel B. Multi-institutional validation of a symptom based classification in renal cell carcinoma. *J Urol*. 2004;172(3):858-62.

Grandgirard N, Ly-Sunnaram B, Ferrant D, Gandemer V, Edan C, Le Gall E, Moulinoux JP, **Leray E**, Goasguen JE. Impact of Topoisomerase II alpha and spermine on the clinical outcome of children with acute lymphoblastic leukemia. *Leuk Res*. 2004;28(5):479-86.

Patard JJ, **Leray E**, Rodriguez A, Rioux-Leclercq N, Guillé F, Lobel B. Correlation between symptom graduation, tumor characteristics and survival in renal cell carcinoma. *Eur Urol*. 2003;44(2):226-32.

Rodriguez A, Kyriakou G, **Leray E**, Lobel B, Guillé F. Prospective study comparing two methods of anaesthesia for prostate biopsies : apex periprostatic nerve block versus intrarectal lidocaine gel; review of the literature. *Eur Urol.* 2003;44(2):195-200.

Sunnaram BL, Gandemer V, Sebillot M, Grandgirard N, Amiot L, **Leray E**, Goasguen JE. LRP overexpression in monocytic lineage. *Leuk Res.* 2003;27(8):755-9.

Patard JJ, Rodriguez A, **Leray E**, Rioux-Leclercq N, Guillé F, Lobel B. Intravesical Bacillus Calmette-Guerin treatment improves patient survival in conservatively treated T1G3 bladder tumours. *Eur Urol.* 2002;41(6):635-41.

Rodriguez A, Tazi H, Kyriakou G, **Leray E**, Lobel B, Guillé F. Blocage nerveux périprostatique au niveau de l'apex versus gel de lidocaine intrarectal. *Prog Urol.* 2002;12(6):1228-33.